Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery
Introduction: Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) in patients with morbid obesity. This study investigates whether duration of diabetes and anti-diabetes therapy are associated with glycaemic control after surgery in a routine clinical setting. Method: A c...
Gespeichert in:
| Veröffentlicht in: | British Journal of Diabetes 2023-06, Vol.23 (1), p.31-34 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 31 |
| container_title | British Journal of Diabetes |
| container_volume | 23 |
| creator | Raja, Haseem Ebrahim, Saarah Mamidanna, Ravikrishna Patel, Krashna Askari, Alan Arhi, Chanpreet Munasinghe, Aruna Rashid, Farhan Al-Taan, Omer Jambulingam, Periyathambi Whitelaw, Douglas Jain, Vigyan Zalin, Anjali Rehman, Tariq Asil, MD Tanveer |
| description | Introduction: Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) in patients with morbid obesity. This study investigates whether duration of diabetes and anti-diabetes therapy are associated with glycaemic control after surgery in a routine clinical setting.
Method: A cohort analysis of a prospectively maintained database was carried out for consecutive bariatric operations performed between April 2017 and March 2018 for patients with T2DM.
Results: A total 105 patients with T2DM underwent bariatric surgery (89 Roux-en-Y gastric bypass and 16 sleeve gastrectomy). Median follow-up was 19 months ([interquartile range] IQR 13-24 months). Median weight and body mass index (BMI) on the day of surgery were 125 kg (IQR 103.9- 138.7) and 42.4 kg/m2 (IQR 39-46.8), respectively. At follow- up, 68 patients (64.8%) had achieved remission of diabetes. Patients who were pre-operatively on more than one glucose-lowering medication were less likely to go into remission (odds ratio [OR] 0.13, 95% CI 0.04-0.44, p=0.001) compared to those that were on a single glucose-lowering medication agent. Pre-operative use of insulin therapy (OR 0.09, 95% CI 0.03-0.31, p=12 months after bariatric surgery. |
| doi_str_mv | 10.15277/bjd.2023.409 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_15277_bjd_2023_409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_15277_bjd_2023_409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c123t-1ecb4eb0980e7b9fcc3be8be0623410ed57b6ff64c0c93ae47e632f55af8e3363</originalsourceid><addsrcrecordid>eNo9kM1qwzAQhEVpoSHNsfd9Aaf6saX4GEL_INBLezaSvHJVHMtISkOeoK9dpwk97bLLzDAfIfeMLlnFlXowX-2SUy6WJa2vyIyLWhWSl-z6fxfilixS8oZySZmSgs7IzzqlYL3OPgxgMB8QBxgjhhHjdPxG6Pq9DQkL6MMBox862GHr7VmhOxxyAj20kD8RUtZ5nyA4yMcRgUPr9WSKadL0vT_9tMsYweg4ZUZvIe1jh_F4R26c7hMuLnNOPp4e3zcvxfbt-XWz3haWcZELhtaUaGi9oqhM7awVBlcG6dSuZBTbShnpnCwttbXQWCqUgruq0m6FQkgxJ8XZ18aQUkTXjNHvdDw2jDZ_IJsJZHMC2UwgxS9ILGrX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Raja, Haseem ; Ebrahim, Saarah ; Mamidanna, Ravikrishna ; Patel, Krashna ; Askari, Alan ; Arhi, Chanpreet ; Munasinghe, Aruna ; Rashid, Farhan ; Al-Taan, Omer ; Jambulingam, Periyathambi ; Whitelaw, Douglas ; Jain, Vigyan ; Zalin, Anjali ; Rehman, Tariq ; Asil, MD Tanveer</creator><creatorcontrib>Raja, Haseem ; Ebrahim, Saarah ; Mamidanna, Ravikrishna ; Patel, Krashna ; Askari, Alan ; Arhi, Chanpreet ; Munasinghe, Aruna ; Rashid, Farhan ; Al-Taan, Omer ; Jambulingam, Periyathambi ; Whitelaw, Douglas ; Jain, Vigyan ; Zalin, Anjali ; Rehman, Tariq ; Asil, MD Tanveer</creatorcontrib><description>Introduction: Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) in patients with morbid obesity. This study investigates whether duration of diabetes and anti-diabetes therapy are associated with glycaemic control after surgery in a routine clinical setting.
Method: A cohort analysis of a prospectively maintained database was carried out for consecutive bariatric operations performed between April 2017 and March 2018 for patients with T2DM.
Results: A total 105 patients with T2DM underwent bariatric surgery (89 Roux-en-Y gastric bypass and 16 sleeve gastrectomy). Median follow-up was 19 months ([interquartile range] IQR 13-24 months). Median weight and body mass index (BMI) on the day of surgery were 125 kg (IQR 103.9- 138.7) and 42.4 kg/m2 (IQR 39-46.8), respectively. At follow- up, 68 patients (64.8%) had achieved remission of diabetes. Patients who were pre-operatively on more than one glucose-lowering medication were less likely to go into remission (odds ratio [OR] 0.13, 95% CI 0.04-0.44, p=0.001) compared to those that were on a single glucose-lowering medication agent. Pre-operative use of insulin therapy (OR 0.09, 95% CI 0.03-0.31, p=<0.001) and SGLT2 inhibitors (OR 0.23, 95% CI 0.05-0.92, p=0.038) were significant negative predictors of remission. Type of operation (p=0.34), pre-operative BMI (p=0.99), and % total weight loss (TWL) (p=0.83) did not predict remission from T2DM after surgery.
Conclusions: Most patients who are medicated for T2DM can stop their glucose-lowering medication after bariatric surgery. Patients who are on multiple glucose-lowering medication agents or those dependent on insulin or SGLT2 inhibitors before bariatric surgery are less likely to undergo complete remission >12 months after bariatric surgery.</description><identifier>ISSN: 2397-6233</identifier><identifier>EISSN: 2397-6241</identifier><identifier>DOI: 10.15277/bjd.2023.409</identifier><language>eng</language><ispartof>British Journal of Diabetes, 2023-06, Vol.23 (1), p.31-34</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Raja, Haseem</creatorcontrib><creatorcontrib>Ebrahim, Saarah</creatorcontrib><creatorcontrib>Mamidanna, Ravikrishna</creatorcontrib><creatorcontrib>Patel, Krashna</creatorcontrib><creatorcontrib>Askari, Alan</creatorcontrib><creatorcontrib>Arhi, Chanpreet</creatorcontrib><creatorcontrib>Munasinghe, Aruna</creatorcontrib><creatorcontrib>Rashid, Farhan</creatorcontrib><creatorcontrib>Al-Taan, Omer</creatorcontrib><creatorcontrib>Jambulingam, Periyathambi</creatorcontrib><creatorcontrib>Whitelaw, Douglas</creatorcontrib><creatorcontrib>Jain, Vigyan</creatorcontrib><creatorcontrib>Zalin, Anjali</creatorcontrib><creatorcontrib>Rehman, Tariq</creatorcontrib><creatorcontrib>Asil, MD Tanveer</creatorcontrib><title>Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery</title><title>British Journal of Diabetes</title><description>Introduction: Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) in patients with morbid obesity. This study investigates whether duration of diabetes and anti-diabetes therapy are associated with glycaemic control after surgery in a routine clinical setting.
Method: A cohort analysis of a prospectively maintained database was carried out for consecutive bariatric operations performed between April 2017 and March 2018 for patients with T2DM.
Results: A total 105 patients with T2DM underwent bariatric surgery (89 Roux-en-Y gastric bypass and 16 sleeve gastrectomy). Median follow-up was 19 months ([interquartile range] IQR 13-24 months). Median weight and body mass index (BMI) on the day of surgery were 125 kg (IQR 103.9- 138.7) and 42.4 kg/m2 (IQR 39-46.8), respectively. At follow- up, 68 patients (64.8%) had achieved remission of diabetes. Patients who were pre-operatively on more than one glucose-lowering medication were less likely to go into remission (odds ratio [OR] 0.13, 95% CI 0.04-0.44, p=0.001) compared to those that were on a single glucose-lowering medication agent. Pre-operative use of insulin therapy (OR 0.09, 95% CI 0.03-0.31, p=<0.001) and SGLT2 inhibitors (OR 0.23, 95% CI 0.05-0.92, p=0.038) were significant negative predictors of remission. Type of operation (p=0.34), pre-operative BMI (p=0.99), and % total weight loss (TWL) (p=0.83) did not predict remission from T2DM after surgery.
Conclusions: Most patients who are medicated for T2DM can stop their glucose-lowering medication after bariatric surgery. Patients who are on multiple glucose-lowering medication agents or those dependent on insulin or SGLT2 inhibitors before bariatric surgery are less likely to undergo complete remission >12 months after bariatric surgery.</description><issn>2397-6233</issn><issn>2397-6241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kM1qwzAQhEVpoSHNsfd9Aaf6saX4GEL_INBLezaSvHJVHMtISkOeoK9dpwk97bLLzDAfIfeMLlnFlXowX-2SUy6WJa2vyIyLWhWSl-z6fxfilixS8oZySZmSgs7IzzqlYL3OPgxgMB8QBxgjhhHjdPxG6Pq9DQkL6MMBox862GHr7VmhOxxyAj20kD8RUtZ5nyA4yMcRgUPr9WSKadL0vT_9tMsYweg4ZUZvIe1jh_F4R26c7hMuLnNOPp4e3zcvxfbt-XWz3haWcZELhtaUaGi9oqhM7awVBlcG6dSuZBTbShnpnCwttbXQWCqUgruq0m6FQkgxJ8XZ18aQUkTXjNHvdDw2jDZ_IJsJZHMC2UwgxS9ILGrX</recordid><startdate>20230628</startdate><enddate>20230628</enddate><creator>Raja, Haseem</creator><creator>Ebrahim, Saarah</creator><creator>Mamidanna, Ravikrishna</creator><creator>Patel, Krashna</creator><creator>Askari, Alan</creator><creator>Arhi, Chanpreet</creator><creator>Munasinghe, Aruna</creator><creator>Rashid, Farhan</creator><creator>Al-Taan, Omer</creator><creator>Jambulingam, Periyathambi</creator><creator>Whitelaw, Douglas</creator><creator>Jain, Vigyan</creator><creator>Zalin, Anjali</creator><creator>Rehman, Tariq</creator><creator>Asil, MD Tanveer</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230628</creationdate><title>Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery</title><author>Raja, Haseem ; Ebrahim, Saarah ; Mamidanna, Ravikrishna ; Patel, Krashna ; Askari, Alan ; Arhi, Chanpreet ; Munasinghe, Aruna ; Rashid, Farhan ; Al-Taan, Omer ; Jambulingam, Periyathambi ; Whitelaw, Douglas ; Jain, Vigyan ; Zalin, Anjali ; Rehman, Tariq ; Asil, MD Tanveer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c123t-1ecb4eb0980e7b9fcc3be8be0623410ed57b6ff64c0c93ae47e632f55af8e3363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raja, Haseem</creatorcontrib><creatorcontrib>Ebrahim, Saarah</creatorcontrib><creatorcontrib>Mamidanna, Ravikrishna</creatorcontrib><creatorcontrib>Patel, Krashna</creatorcontrib><creatorcontrib>Askari, Alan</creatorcontrib><creatorcontrib>Arhi, Chanpreet</creatorcontrib><creatorcontrib>Munasinghe, Aruna</creatorcontrib><creatorcontrib>Rashid, Farhan</creatorcontrib><creatorcontrib>Al-Taan, Omer</creatorcontrib><creatorcontrib>Jambulingam, Periyathambi</creatorcontrib><creatorcontrib>Whitelaw, Douglas</creatorcontrib><creatorcontrib>Jain, Vigyan</creatorcontrib><creatorcontrib>Zalin, Anjali</creatorcontrib><creatorcontrib>Rehman, Tariq</creatorcontrib><creatorcontrib>Asil, MD Tanveer</creatorcontrib><collection>CrossRef</collection><jtitle>British Journal of Diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raja, Haseem</au><au>Ebrahim, Saarah</au><au>Mamidanna, Ravikrishna</au><au>Patel, Krashna</au><au>Askari, Alan</au><au>Arhi, Chanpreet</au><au>Munasinghe, Aruna</au><au>Rashid, Farhan</au><au>Al-Taan, Omer</au><au>Jambulingam, Periyathambi</au><au>Whitelaw, Douglas</au><au>Jain, Vigyan</au><au>Zalin, Anjali</au><au>Rehman, Tariq</au><au>Asil, MD Tanveer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery</atitle><jtitle>British Journal of Diabetes</jtitle><date>2023-06-28</date><risdate>2023</risdate><volume>23</volume><issue>1</issue><spage>31</spage><epage>34</epage><pages>31-34</pages><issn>2397-6233</issn><eissn>2397-6241</eissn><abstract>Introduction: Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) in patients with morbid obesity. This study investigates whether duration of diabetes and anti-diabetes therapy are associated with glycaemic control after surgery in a routine clinical setting.
Method: A cohort analysis of a prospectively maintained database was carried out for consecutive bariatric operations performed between April 2017 and March 2018 for patients with T2DM.
Results: A total 105 patients with T2DM underwent bariatric surgery (89 Roux-en-Y gastric bypass and 16 sleeve gastrectomy). Median follow-up was 19 months ([interquartile range] IQR 13-24 months). Median weight and body mass index (BMI) on the day of surgery were 125 kg (IQR 103.9- 138.7) and 42.4 kg/m2 (IQR 39-46.8), respectively. At follow- up, 68 patients (64.8%) had achieved remission of diabetes. Patients who were pre-operatively on more than one glucose-lowering medication were less likely to go into remission (odds ratio [OR] 0.13, 95% CI 0.04-0.44, p=0.001) compared to those that were on a single glucose-lowering medication agent. Pre-operative use of insulin therapy (OR 0.09, 95% CI 0.03-0.31, p=<0.001) and SGLT2 inhibitors (OR 0.23, 95% CI 0.05-0.92, p=0.038) were significant negative predictors of remission. Type of operation (p=0.34), pre-operative BMI (p=0.99), and % total weight loss (TWL) (p=0.83) did not predict remission from T2DM after surgery.
Conclusions: Most patients who are medicated for T2DM can stop their glucose-lowering medication after bariatric surgery. Patients who are on multiple glucose-lowering medication agents or those dependent on insulin or SGLT2 inhibitors before bariatric surgery are less likely to undergo complete remission >12 months after bariatric surgery.</abstract><doi>10.15277/bjd.2023.409</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2397-6233 |
| ispartof | British Journal of Diabetes, 2023-06, Vol.23 (1), p.31-34 |
| issn | 2397-6233 2397-6241 |
| language | eng |
| recordid | cdi_crossref_primary_10_15277_bjd_2023_409 |
| source | EZB-FREE-00999 freely available EZB journals |
| title | Association between preoperative glucose- lowering medication agents and the status of type 2 diabetes mellitus after bariatric surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T20%3A16%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20preoperative%20glucose-%20lowering%20medication%20agents%20and%20the%20status%20of%20type%202%20diabetes%20mellitus%20after%20bariatric%20surgery&rft.jtitle=British%20Journal%20of%20Diabetes&rft.au=Raja,%20Haseem&rft.date=2023-06-28&rft.volume=23&rft.issue=1&rft.spage=31&rft.epage=34&rft.pages=31-34&rft.issn=2397-6233&rft.eissn=2397-6241&rft_id=info:doi/10.15277/bjd.2023.409&rft_dat=%3Ccrossref%3E10_15277_bjd_2023_409%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |